Trials / Completed
CompletedNCT04440345
Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI362 in Overweight or Obesity Subjects
Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI362 in Overweight or Obese Subjects
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This trial is conducted in China. The aim of this trial is to investigate Safety, Tolerability, PK and PD for Multiple Doses of IBI362 in Overweight or Obese Male and Female Subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IBI362 | Administered by subcutaneous injection |
| DRUG | Placebo | Administered by subcutaneous injection |
Timeline
- Start date
- 2020-06-16
- Primary completion
- 2021-06-16
- Completion
- 2021-08-06
- First posted
- 2020-06-19
- Last updated
- 2023-11-28
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04440345. Inclusion in this directory is not an endorsement.